Entera Bio (NASDAQ:ENTX) Trading Down 3.1% – Here’s Why

Entera Bio Ltd. (NASDAQ:ENTX) was down 3.1% on Tuesday . The company traded as low as $1.57 and last traded at $1.57. Approximately 133,504 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 267,867 shares. The stock had previously closed at $1.62.

Analyst Upgrades and Downgrades

Several research analysts have commented on ENTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, December 27th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Entera Bio Trading Down 3.1%

The firm’s 50-day moving average price is $2.05 and its 200 day moving average price is $2.08. The company has a market cap of $72.00 million, a price-to-earnings ratio of -6.28 and a beta of 1.78.

Entera Bio (NASDAQ:ENTX) last issued its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Analysts forecast that Entera Bio Ltd. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Entera Bio stock. Citadel Advisors LLC grew its position in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 243.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,978 shares of the company’s stock after acquiring an additional 28,322 shares during the quarter. Citadel Advisors LLC owned about 0.09% of Entera Bio worth $77,000 as of its most recent filing with the Securities & Exchange Commission. 14.11% of the stock is owned by institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.